VBI Vaccines Inc. (VBV) Analysts See $-0.31 EPS

March 18, 2018 - By Adrian Mccoy

 VBI Vaccines Inc. (VBV) Analysts See $ 0.31 EPS

Analysts expect VBI Vaccines Inc. (TSE:VBV) to report $-0.31 EPS on March, 23.They anticipate $0.07 EPS change or 29.17 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS previously, VBI Vaccines Inc.’s analysts see 3.33 % EPS growth. The stock increased 3.16% or $0.16 during the last trading session, reaching $5.22. About 6,487 shares traded or 93.99% up from the average. VBI Vaccines Inc. (TSE:VBV) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $332.35 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.